ヨーロッパのバイオインフォマティクス市場における AI – 業界動向と 2029 年までの予測

ヨーロッパのバイオインフォマティクスにおける AI 市場の分析と規模

遺伝子配列決定コストの削減により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に起因しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げとサービスの承認に重点を置いています。さらに、バイオインフォマティクスの需要の高まりと、バイオインフォマティクスに対する官民セクターの資金の増加も、市場の需要の高まりに貢献しています。

欧州のバイオインフォマティクスにおける AI 市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場で新しいサービスを開始するための研究開発活動に取り組んでいます。バイオインフォマティクス技術の進歩が進むことで、市場の成長がさらに加速しています。ただし、バイオインフォマティクスにおける計測機器の高コストとサイバーセキュリティの懸念により、予測期間中の欧州のバイオインフォマティクスにおける AI 市場の成長が妨げられる可能性があります。

Data Bridge Market Research の分析によると、バイオインフォマティクスにおける AI 市場は、予測期間中に 43.0% の CAGR で成長し、2029 年までに 110 億 2,314 万米ドルに達すると予想されています。バイオインフォマティクスにおけるハンドヘルド AI の使用を商業化する技術経路が急速に発展しているため、「サービス」がバイオインフォマティクスにおける AI 市場で最大の技術セグメントを占めています。バイオインフォマティクスにおける AI 市場レポートでは、価格分析、特許分析、技術の進歩についても詳細に取り上げています。         

Market Definition

Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes and other sequences in proteins and other sequences within an organism or between organisms, looking at the evolutionary relationships between organisms, and using the patterns that exist across DNA and protein sequences to figure out what their function is.

Bioinformatics combines computer programming, big data, and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.

From genetics to toxicology to mycology and radiobiology, there are scores of branches of Biology to specialize in. And out of the many, Bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store, and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics, and biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics, and others.

In the coming future, important decisions related to bioinformatics, on drug discovery will be made by individuals who not only understand the biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

AI in Bioinformatics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

• Growing demand for bioinformatics

As genomics focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into the molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public, and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which, in turn, have improved the quality of these services.

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated and need high validation and other specification which increase. Genomics instruments are also equipped with advanced features and functionalities and are thus priced at a premium, ranging between ~USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity, and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes and engage patients more.

Companies discover and develop advanced bioinformatics products, and these companies are launching new initiatives and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology up-gradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications, and there are high chances of the advancement of bioinformatics techniques in the forecasted period.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves the development and use of computational tools for the collection, archiving, organization, analysis, and visualization of biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualization of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

Post COVID-19 Impact on AI in Bioinformatics Market

During the pandemic, the North bioinformatics sector is one that focused on using the combination of biology and information technology. At the heart of the industry is biological data, which is analyzed and transformed using IT techniques. Bioinformatics has always had huge potential when it comes to providing essential support to many areas of scientific research. The tools that bioinformatics can provide allow scientists to get to grips with larger data sets to mine and analyses them to discover crucial information that could lead to key discoveries. Genetics and genomes have been the primary focus of bioinformatics in recent years, including comparative genomics, DNA microarrays, and functional genomics.

The growth of the AI in bioinformatics market is increasing with the growing demand for analysis tools in drug discovery and development and the integration of AI in various fields to interpret the data more conveniently. Hence, the market is expected to grow significantly in the forecast period, whereas the cost and the complexity of AI integration may hamper the market growth. The intervention of COVID-19 has increased the R&D activities, which in turn positively add to the market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped company to increase their Europe presence in the market.
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company in Europe servicing clients in the life sciences, biotechnology, and pharmaceutical industries. JADBio is a robust Automated Machine Learning platform that allows intuitive, timely, and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Europe AI in Bioinformatics Market Scope

Europe AI in bioinformatics market is segmented on the basis of offering, type, products and services, application, and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

On the basis of offering, the Europe AI in bioinformatics market is segmented into services, software, and others.

Type

• Machine Learning
• Deep Learning
• Others

On the basis of type, the Europe AI in bioinformatics market has been segmented into machine learning, deep learning, and others.

Products and Services

• Bioinformatics Services
• Bioinformatics Platforms
• Knowledge Management Tools

On the basis of products and services, the Europe AI in bioinformatics market has been segmented into bioinformatics services, bioinformatics platforms, and knowledge management tools.

Application

• Genomics
• Chemoinformatics & Drug Design
• Proteomics
• DNA Sequencing
• System Biology
• Transcriptomics
• Text Mining
• Microarrays
• Metabolomics
• Others

On the basis of application, the Europe AI in bioinformatics market has been segmented into below genomics, chemoinformatics & drug design, proteomics, DNA sequencing, system biology, transcriptomics, text mining, microarrays, metabolomics and others.

Sector

• Medical Biotechnology
• Animal Biotechnology
• Plant Biotechnology
• Environmental Biotechnology
• Forensic Biotechnology
• Others

On the basis of sector, the Asia-Pacific AI in bioinformatics market has been segmented into medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, and others.

AI in Bioinformatics Market Regional Analysis/Insights

The AI in bioinformatics market is analyzed, and market size insights and trends are provided by country, offering, type, products and services, application, and the sector as referenced above.

The countries covered in the Europe AI in bioinformatics market report are U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey and Rest of Europe. U.K. is expected to dominate the Europe AI in bioinformatics market due to growing start-ups focusing on AI technology in bioinformatics and the rising demand for bioinformatics and its high application in research and development.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing a forecast analysis of the country data.   

Competitive Landscape and AI in Bioinformatics Market Share Analysis

バイオインフォマティクスにおける AI 市場の競争環境では、競合他社の詳細が提供されます。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、ヨーロッパでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、バイオインフォマティクスにおける AI 市場への会社の重点にのみ関連しています。

バイオインフォマティクス市場における AI に携わる主要企業としては、JADBio & Gnosis Data Analysis、Fios Genomics、SOPHiA GENETICS、Biomax Informatics Inc.、Ardigen (親会社 Selvita Group)、Source BioScience、QIAGEN、NeoGenomics Laboratories、Eurofins Scientific、Illumina, Inc.、Thermo Fisher Scientific, Inc.、Insilico Medicine、Dassault Systèmes、SomaLogic Operating Co., Inc. などが挙げられます。

SKU-69029